Methoxyamine

Developed for: lung adenocarcinoma · lung large cell carcinoma · adult glioblastoma · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · angioimmunoblastic T-cell lymphoma · Burkitt lymphoma · cancer of unknown primary site
+27 more
· chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic myeloid leukemia · extranodal nasal NK/T cell lymphoma · grade III lymphomatoid granulomatosis · hepatosplenic T-cell lymphoma · Hodgkins lymphoma · intraocular lymphoma · large-cell immunoblastic lymphoma · lymphoblastic lymphoma · lymphoma · maligant granulosa cell tumor of ovary · malignant peritoneal mesothelioma · malignant pleural mesothelioma · MALT lymphoma · mantle cell lymphoma · metastasis from malignant tumor of colon · mycosis fungoides and variants · neoplasm · nodal marginal zone B-cell lymphoma · non-small cell lung carcinoma · peripheral T-cell lymphoma, not otherwise specified · plasma cell myeloma · primary cutaneous B-cell lymphoma · small intestine lymphoma · splenic marginal zone lymphoma · testicular lymphoma · Waldenstrom macroglobulinemia
Investigated by: National Cancer Institute (NCI) · Case Comprehensive Cancer Center · Tracon Pharmaceuticals Inc.

200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 14 trials
Phase 1	NCT02535325	Sep 2015 → Feb 2020	lung adenocarcinoma, lung large cell carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01658319	May 2011 → Feb 2015	Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +20	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1	NCT00692159	Jun 2008 → Jun 2010	neoplasm	Tracon Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 1	NCT00892385	Aug 2007 → Mar 2017	cancer of unknown primary site	Case Comprehensive Cancer Center	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT02535312	Mar 2016 → Dec 2022 overdue	malignant peritoneal mesothelioma, malignant pleural mesothelioma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT01851369	Jul 2013 → Aug 2023	lymphoma, maligant granulosa cell tumor of ovary, metastasis from malignant tumor of colon, non-small cell lung carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT05198830	Dec 2022 → Jun 2027 expected	lung adenocarcinoma, lung large cell carcinoma	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 2	NCT02395692	Dec 2015 → Feb 2017	adult glioblastoma	National Cancer Institute (NCI)	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	methoxyamine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198830 ↗ 5 NCT02395692 ↗ NCT01658319 ↗ NCT00892385 ↗ NCT02535325 ↗ NCT02535312 ↗
Known as	Methoxyamine hcl	ChEMBL registry synonym — accepted as the source's own label CHEMBL1213633 ↗
Known as	Methoxyamine Hydrochloride	“Drug: Methoxyamine Hydrochloride” NCT02535325 ↗
Known as	NSC-3801	ChEMBL registry synonym — accepted as the source's own label CHEMBL1213633 ↗
Known as	TRC102	“This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination usual care treatment comprised of pemetrexed, cisplatin or carboplatin, and radiation...” NCT05198830 ↗ 3 “methoxyamine (TRC102)” NCT02535312 ↗ NCT00692159 ↗ NCT01851369 ↗
Action	Inhibit	“TRC102 (methoxyamine hydrochloride (HCl) acts through a novel mechanism to inhibit BER” NCT01851369 ↗
Modality	Small molecule	— CHEMBL1213633 ↗
Route	Oral	“Oral TRC102 solution” NCT00692159 ↗